Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Breast Diseases (Phase 2)
Breast Neoplasms (Phase 4)
Capecitabine (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Transitional Cell (Phase 4)
Colorectal Neoplasms (Phase 4)
Cystectomy (Phase 4)
Drugs, Investigational (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Genes, erbB-2 (Phase 3)
Genital Neoplasms, Female (Phase 2)
Immunoconjugates (Phase 2)
Immunotherapy (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Melanoma (Phase 2)
Neoadjuvant Therapy (Phase 4)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Radiotherapy (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 4)
Uterine Cervical Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue